Prospectus Supplement

• Anteris filed a Prospectus Supplement with the SEC for a public offering of 34,782,609 shares of common stock
• Concurrent private placement of 15,652,173 shares to Covidien Group S.à r.l., a subsidiary of Medtronic plc
• Offering proceeds to support the development and commercialization of Anteris' lead product, the DurAVR® Transcatheter Heart Valve System

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a global structural heart company, has filed a Prospectus Supplement with the U.S. Securities and Exchange Commission (SEC) for a public offering of 34,782,609 shares of its common stock. Concurrently, the company has agreed to sell 15,652,173 shares of common stock to Covidien Group S.à r.l., a wholly-owned subsidiary of Medtronic plc, in a private placement. The public offering price for each share of common stock is $5.75. The proceeds from the offering and private placement will be used to support the development and commercialization of Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV) System. The DurAVR® THV System is a single-piece, biomimetic valve designed to treat aortic stenosis, a potentially life-threatening condition resulting from a narrowing of the aortic valve. The system utilizes Anteris' proprietary ADAPT® tissue-enhancing technology and the balloon-expandable ComASUR® Delivery System. The safety and efficacy of the DurAVR® THV System are currently being evaluated in the PARADIGM Trial, with the first patients enrolled and implanted in Denmark during the fourth quarter of 2025.

Anteris has not provided any high-importance, price-sensitive forward-looking financial metrics or guidance in the announcement.

The announcement does not contain any forward-looking outlook statements.